Search
Now showing items 1-10 of 29
Toxicogenomic late effects of antineoplastic therapies for lymphomas
(Wiley-Blackwell, 2011-10-01)
Toxicogenomics: new strategies for ecotoxicology studies in autochthonous species II : The 'omic' era in non-model species : Transcriptome analysis for biomarker screening
(Inderscience Enterprises, 2017-06)
The emerging field of ecotoxicogenomics aims to combine large-scale approaches to study the responses of organisms to a toxicant. A holistic vision of gene and protein expression in response to toxic exposure contributes ...
Relationship between head and neck cancer therapy and some genetic endpoints
(Baishideng Publishing Group Inc, 2014-05-10)
Head and neck cancer (HNC) is the sixth most common human malignancy worldwide. The main forms of treatment for HNC are surgery, radiotherapy (RT) and chemotherapy (CT). However, the choice of therapy depends on the tumor ...
Prediction of non-genotoxic carcinogenicity based on genetic profiles of short term exposure assays
(Korean Society of Toxicology, 2016-06)
Non-genotoxic carcinogens are substances that induce tumorigenesis by non-mutagenic mechanisms and long term rodent bioassays are required to identify them. Recent studies have shown that transcription profiling can be ...
Relationship between head and neck cancer therapy and some genetic endpoints
(Baishideng Publishing Group Inc, 2015)
Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response
(2017-09-01)
Transmissible venereal tumour (TVT) generally presents different degrees of aggressiveness, which makes them unresponsive to conventional treatment protocols. This implies a progressive alteration of their biological ...
Toxicogenomic late effects of antineoplastic therapies for lymphomas
(Wiley-Blackwell, 2014)
Mechanisms Of In-stent Restenosis: A Toxicogenomic In Vitro Study Using Coronary Artery Endothelial And Smooth Muscle Cells
(WILEY-BLACKWELLHOBOKEN, 2015)
Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes
(Springer, 2012-12-01)
Because of its lower toxicity and good tolerability and response, gemcitabine has been described as one of the most highly promising drugs for urinary bladder cancer therapy. Its phosphorylated active-dFdCTP metabolite can ...